Preferred product characteristics and clinical development considerations
Le Infezioni in Medicina, n. 1, 3-10, 2019
A historic funding crisis is threatening to unravel decades of progress unless countries can make radical shifts to HIV programming and funding. The report highlights the impact that the sudden, large-scale funding cuts from international donors are having on countries most affected by HIV. Yet it a...lso showcases some inspiring examples of resilience, with countries and communities stepping up in the face of adversity to protect the gains made and drive the HIV response forward.
more
Access to safe, effective and quality-assured health products and technologies is crucial for achieving universal health coverage and primary health care goals. The continued growth of the aging population; increasing burden of noncommunicable diseases; growing burden of mental health issues; climat...e change; shifting patterns of vector borne diseases, fungal disease and waterborne diseases; antimicrobial resistance; and new infectious hazards create an ongoing need for equitable access to safe, effective and quality-assured health products and technologies, and renewed investments in research and development for innovative health products and technologies.
The coronavirus pandemic exposed the inequalities in access to health products, highlighting the need for longer-term strategies to strengthen access to health products and technologies outside of and in emergency situations. While technological and scientific advances present an opportunity to increase access to health products and technologies, the risk of increasing inequality due to higher prices for new health products and technologies; the persisting problem of substandard and falsified medical products; a lack of skilled workforce in many low- and middle-income countries; and a lack of data for decisionmaking and for measuring progress present significant challenges.
more
Despite being a preventable and curable infectious disease, tuberculosis (TB) has continued to elude global controll efforts. In 2023, 8.2 milion people with TB were diagnosed and notified to the WHO, the hightest number ever reported since WHO began tracking.
This guidance synthesizes current evidence on dengue laboratory testing and diagnostics and provides practical recommendations for laboratories, clinicians, public health officials, and programme managers involved in dengue diagnosis, surveillance, and control, in the context of the global emergency.... It includes a diagnostic algorithm for suspected cases, outlining appropriate testing methods based on days post symptom onset.
more
These Frequently Asked Questions (FAQs) have been developed by the Infant Feeding in Emergencies (IFE) Core Group Infectious Disease Working Group based on the most recent recommendations, collective knowledge and evidence on cholera. The FAQs also draw on infant and young child feeding (IYCF) recom...mendations from the World Health Organization (WHO) and the Infant Feeding in Emergencies Core Group (IFE CG). These FAQs are intended to provide answers to health workers and the public – including mothers who are breastfeeding or expressing milk – on breastfeeding during a cholera outbreak.
more
Ces questions fréquemment posées (FAQs) ont été élaborées par le Groupe de travail sur les maladies infectieuses du Groupe l'alimentation central sur des nourrissons en situation d'urgence (IFE) en se basant sur les recommandations les plus récentes, les connaissances collectives et les donn...es probantes relatives au choléra. Les questions fréquemment posées (FAQs) s'appuient également sur les recommandations de l'Organisation mondiale de la santé (OMS) et du Groupe central sur l'alimentation des nourrissons en situation d'urgence (IFE CG) en matière d'alimentation des nourrissons et des jeunes enfants (IYCF). Ces FAQs ont pour objectif de fournir des réponses aux professionnels de santé ainsi qu’au grand public- y compris aux mères qui allaitent ou qui tirent leur lait- au sujet de l'allaitement maternel lors d'une épidémie de choléra.
Cesquestions fréquentesreflètent:
•Les preuves disponibles et les derniers outils de lutte contre le choléra du Groupe de travail mondial sur la lutte contre le choléra (2025) et de l'UNICEF (2013)
•Les effets protecteurs du lait maternel et de l'allaitement
•Les effets néfastes liés à l'utilisation inappropriée de substituts de lait maternel
more
Anxiety Disorders
Chapter F.4
Antimicrobial resistance (AMR) is a multifaceted, international public health problem, which poses a direct threat to the safety of the population of South Africa. A national response is required to complement the development of a global plan, as articulated in the WHO’s draft resolution EB134/37 ...“Combating antimicrobial resistance including antibiotic resistance”, adopted by theWorld Health Assembly in May 2014. The overuse of antimicrobials is driving resistance. A return to appropriate, targeted antimicrobial use in humans, animals and the environment is critical if we are to conserve the antimicrobial armamentarium. Various interventions have been put in place to address antimicrobial resistance in South Africa. However, these are insufficient to effectively tackle the threat faced by the country. The strengths of the current system are outweighed by its weaknesses.
more
Antimicrobial resistance has become a serious public health threat for effective treatment of an ever increasing range of infections caused by bacteria, parasites, viruses and fungi. When infections can no longer be treated by first-line antibiotics, other antibiotics must be used, which are both mo...re expensive and more toxic. Treatment and hospitalization is prolonged, and patients undergoing operations and other medical procedures are more vulnerable to infections. All this imposes a huge burden on health care systems and on the economy of countries. This is a major challenge to the health system in Mauritius which provides health care free of user cost to the whole population.
more
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
The global emergence of antimicrobial resistance (AMR) is posing a threat to human health. Putting resources into the containment of AMR – including surveillance – is one of the highest-yield investments a country can make to mitigate its impact. In 2015, WHO launched the Global Antimicrobial Re...sistance Surveillance System (GLASS), the first global collaborative effort to foster AMR surveillance in bacteria causing acute infections. As of December 2018, 71 countries are enrolled in GLASS. The aim of this report is to document participation efforts and outcomes across these countries, and highlight differences and constraints identified to date. This report follows on from the first GLASS Report – Early implementation 2016-17, published in January 2018, and drawing on data from GLASS first data call in 2017.
more
Interim guidance, 6 October 2021
Direct detection of SARS-CoV-2 viral proteins (antigens) in nasal swabs and other respiratory secretions using lateral flow immunoassays (also known as rapid diagnostic tests, RDTs) offers a faster and less expensive method to test for SARS-CoV-2 than the reference ...method, nucleic acid amplification tests (NAATs). This interim guidance offers recommendations on the priority uses of antigen-detecting rapid diagnostic tests (Ag-RDTs) in specific populations and settings, including (i) for primary case detection in symptomatic individuals suspected to be infected and asymptomatic individuals at high risk of COVID-19, (ii) for contact tracing, (iii) during outbreak investigations and (iv) to monitor trends of disease incidence in communities. Ag-RDTs meeting minimum performance requirements can be used outside of clinical and laboratory settings, including in communities, by trained operators in accordance with instructions. The guidance additionally provides recommendations on implementation, product selection and storage.
more